COMUNICATO STAMPA
Relazione sulla Remunerazione MolMed S.p.A.
Aptamer-Based Antibacterial and Antiviral Therapy against Infectious Diseases | Journal of Medicinal Chemistry
MolMed: AIFA approva commercializzazione Zalmoxis. Titolo vola in Borsa - Economia e Finanza - Repubblica.it
MolMed: Contact Details and Business Profile
Overview of the Italian Primary Markets
Il 2019 è l'anno della svolta per MolMed - MilanoFinanza.it
European Population Genetic Substructure: Further Definition of Ancestry Informative Markers for Distinguishing among Diverse European Ethnic Groups | Molecular Medicine | Full Text
Antioxidants | Free Full-Text | Cellular Aging Characteristics and Their Association with Age-Related Disorders
Press release issued by MolMed S.p.A. at the request of AGC Inc. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PA
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHER
Press release issued by MolMed S.p.A. upon request of AGC Inc. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART
I giapponesi di Agc l'anciano un'Opa su Molmed e il titolo corre in borsa
MolMed receives IND clearance by the FDA to conduct a Phase III trial of TK for high-risk leukaemia in the United States
Will MolMed soon have its first Cell therapy on the Market?
Innovazione, la Borsa corre con plastica e super batteri - Corriere.it
Molmed, Opa dei giapponesi di Agc. Per Berlusconi 30 milioni di plusvalenza - Affaritaliani.it
Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer - ScienceDirect
Il gioiello biotech MolMed ai giapponesi. Inizia così lo shopping a Piazza Affari - Formiche.net
1 - [Note: this notice is the English translation of the official version of the 102 notice which will be in Italian language]
MOLMED S.P.A. : MLM Stock Price | IT0001080248 | MarketScreener
